Prosecution Insights
Last updated: April 19, 2026
Application No. 18/630,366

HEART VALVE COAPTATION DEVICE

Final Rejection §102§103§112
Filed
Apr 09, 2024
Examiner
MCEVOY, THOMAS M
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Edwards Lifesciences Corporation
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
3y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
704 granted / 994 resolved
+0.8% vs TC avg
Strong +36% interview lift
Without
With
+35.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
55 currently pending
Career history
1049
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
50.3%
+10.3% vs TC avg
§102
28.0%
-12.0% vs TC avg
§112
17.0%
-23.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 994 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 12 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. It is unclear whether the “resilient wing members” are the same structures as the “resilient wing members” recited in claim 11 or not. The specification does not disclose more than one wing member per outer portion. For the purpose of this examination, the resilient wing members recited in claim 12 are determined to be the same structure as the resilient wing members recited in claim 11. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 15 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 15 depends from cancelled claim 14. Applicant may cancel the claim, amend the claim to place the claim in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 5, 8, 9, 13 and 16 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Kizuka et al. (US 2018/0133008; hereinafter “Kizuka”; cited by Applicant in parent application 17/163215). Regarding claim 1, Kizuka discloses a device for repairing a heart valve (Abstract; Figure 9E), comprising: a first clip (10’) comprising an inner portion (12) and an outer portion (14 or 14/20), wherein the inner and outer portions of the first clip are configured to compress tissue of a first heart valve leaflet (“AL”; Figure 9E) therebetween to secure the first clip to the first leaflet; a second clip (10’’) comprising an inner portion (12) and an outer portion (14), wherein the inner and outer portions of the second clip are configured to compress tissue of a second heart valve leaflet (“PL”; Figure 9E) therebetween to secure the second clip to the second leaflet; a post (16) that includes a lumen , wherein the post is coupled to the second clip (each clip has a post - Figure 9E); a tether (86) coupled to at least the first clip (via the post; noting that Applicant’s tether is not fixedly connected to either clip): wherein the tether extends through the lumen of the post (Figure 9E) and wherein the first and second clips are configured to be separately deployable onto the first and second leaflets (evident from Figures 9A and 9B) and secured to one another in vivo by applying tension to the tether to bring the first clip into closer proximity with the post and the second clip (¶[0077]). Regarding claim 5, the device comprises a locking member (90) configured to engage the tether and thereby secure the first and second clips to one another (¶[0072]). Regarding claim 8, the device further comprises: a third clip (10’’’; Figure 12) comprising an inner portion (12) and an outer portion (14), wherein the inner and outer portions are configured to compress tissue of a third heart valve leaflet (“Septal leaflet” - Figure 12) therebetween to secure the third clip to the third leaflet; wherein the third clip is configured to be separately deployable onto the third leaflet (as shown for the first and second clips - Figure 9A-9B) and secured to the first and second clips in vivo to bring portions of the third leaflet in closer proximity to the first and second leaflets, thereby improving coaptation of the first, second, and third leaflets (¶[0077], [0079]). Regarding claim 9, Kizuka discloses a system for repairing a heart valve (Abstract), comprising: an elongate delivery catheter (38) comprising at least one lumen; a heart valve repair device (10’/10’’) coupled to the elongate delivery catheter (Figure 6A), the heart valve repair device comprising: a first clip (10’; Figure 9E) comprising an inner portion (12) and an outer portion (14 or 14/20), wherein the inner and outer portions are configured to compress tissue (“AL”; Figure 9E) of a first heart valve leaflet therebetween to secure the first clip to the first leaflet; a second clip (10’’; Figure 9E) comprising an inner portion (12) and an outer portion (14), wherein the inner and outer portions are configured to compress tissue (“PL”; Figure 9E) of a second heart valve leaflet therebetween to secure the second clip to the second leaflet; a post (16) that includes a lumen, wherein the post is coupled to the second clip; wherein the second clip includes a post defining a lumen (within 82 and/or lumen 24); a tether (86) coupled to at least the first clip (via the post; noting that Applicant’s tether is not fixedly connected to either clip); wherein the tether extends through the lumen of the post (Figure 9E); and wherein the first and second clips are configured to be separately deployable onto the first and second leaflets (evident from Figures 9A and 9B) and secured to one another in vivo by applying tension to the tether to bring the first clip into closer proximity with the post and the second clip (¶[0077]). Regarding claim 13, the system further comprises a locking member (90) configured to engage the tether and thereby secure the first and second clips to one another (¶[0072]). Regarding claim 16, the system further comprises: a third clip (10’’’; Figure 12) comprising an inner portion (12) and an outer portion (14), wherein the inner and outer portions are configured to compress tissue of a third heart valve leaflet (“Septal leaflet”; Figure 12) therebetween to secure the third clip to the third leaflet; wherein the third clip is configured to be separately deployable onto the third leaflet (as shown for the first and second clips - Figure 9A-9B) and secured to the first and second clips in vivo to bring portions of the third leaflet in closer proximity to the first and second leaflets, thereby improving coaptation of the first, second, and third leaflets (¶[0077], [0079]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or non-obviousness. Claims 3, 11 and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Kizuka in view of Goldfarb et al. (US 2010/0022823; hereinafter “Goldfarb”; cited by Applicant in parent application 15/843995). Regarding claims 3, 11 and 12, Kizuka discloses that the outer portions of the first and second clips each comprise a frame (14/20) having a wing member (14) but fails to disclose that the wing members are resilient. Goldfarb teaches that similar wing members (18) can be made of a resilient metal or polymer in order to prevent damage to a leaflet (¶[0074]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention and in view of Goldfarb to have made the wing members of Kizuka from a resilient metal or polymer in order to prevent damage to the leaflets. Response to Arguments Applicant’s arguments with respect to the pending claims have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas McEvoy whose telephone number is (571) 270-5034 and direct fax number is (571) 270-6034. The examiner can normally be reached on Monday-Friday, 9:00 am – 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner’s supervisor, Elizabeth Houston at (571) 272-7134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /THOMAS MCEVOY/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Apr 09, 2024
Application Filed
Sep 30, 2025
Non-Final Rejection — §102, §103, §112
Dec 22, 2025
Response Filed
Mar 26, 2026
Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594069
Handle Assembly Providing Unlimited Roll
2y 5m to grant Granted Apr 07, 2026
Patent 12564405
BLOOD VESSEL COMPRESSION SYSTEMS
2y 5m to grant Granted Mar 03, 2026
Patent 12558242
ANATOMIC NEEDLE SYSTEM
2y 5m to grant Granted Feb 24, 2026
Patent 12544072
TISSUE ANCHOR FOR SECURING TISSUE LAYERS
2y 5m to grant Granted Feb 10, 2026
Patent 12544106
Puncture guide needle
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+35.6%)
3y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 994 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month